Rapport Therapeutics FY Conference Summary Company Overview - Company: Rapport Therapeutics (NasdaqGM:RAPP) - Industry: Biotechnology, specifically focusing on neuroscience and epilepsy treatments Key Highlights from 2025 and Early 2026 - 2025 was a transformational year for Rapport, showcasing confirmatory data for their approach in precision neuroscience, particularly with their lead program RAP-219 targeting focal-onset seizures [3][4] - Proof-of-concept data released in September 2025 demonstrated a 72% reduction in a novel biomarker and a 78% reduction in clinical seizures in a refractory patient population [4][5] - A 24% seizure freedom rate was also reported, allowing progression into registrational studies [5] Upcoming Clinical Trials - Phase 3 program for RAP-219 will be initiated in Q2 2026, accelerated from Q3 due to positive FDA interactions [5] - Two pivotal trials will be conducted in parallel, focusing on refractory focal-onset seizure patients, with three dose levels: low (0.25 mg), mid (0.75 mg), and high (1.25 mg) [6][7] Patient Population Insights - The proof-of-concept study enrolled patients with an RNS device, showing demographic similarities to those in traditional studies, but with a higher refractory rate [8][9] - 70% of enrolled patients were on 3-4 medications, indicating a highly refractory population [9] Efficacy and Safety Expectations - A clinically meaningful placebo-adjusted seizure reduction target is set at 30%-35%, with a non-placebo adjusted target of 50%-55% [10] - Emphasis on tolerability and ease of administration is crucial for market adoption, with a preference for once-daily dosing and minimal drug-drug interactions [11][12] Tolerability Profile - The phase 2 study reported only mild to moderate adverse events (AEs), with no severe AEs observed [14] - Anxiety was noted in some patients, but it was attributed to preexisting conditions rather than the drug itself [15][16] Market Opportunity - The market opportunity for RAP-219 in focal-onset seizures is estimated at $2.5 billion, based on a refractory population of 30%-40% of 1.8 million patients [18] - A long-acting injectable formulation is also in development, which could further enhance market potential [19] Long-Acting Injectable Insights - KOLs believe a long-acting injectable would be transformational for patients, addressing concerns about missed doses leading to breakthrough seizures [20][21] - The development of RAP-219 as a long-acting injectable is supported by its extended half-life and low solubility, making it suitable for this formulation [22][23] Enrollment and Trial Dynamics - Current trends show varying enrollment timelines for pivotal studies, with some taking 2-4 years [25] - Rapport aims to leverage excitement in the community and the completion of other ongoing trials to facilitate patient recruitment [26][27] Bipolar Mania Program - RAP-219 is also being explored for bipolar mania, with a focus on its potential to reduce excessive glutamate associated with the condition [28][29] - The primary endpoint for the bipolar mania trial is the Young Mania Rating Scale (YMRS), with a meaningful effect defined as a 4-point placebo-adjusted change [35] Pain Program Focus - The company has shifted focus to a nicotinic acetylcholine receptor program for pain, which has shown promise in preclinical models [37][38] Financial Outlook - Rapport is funded into the second half of 2029, allowing for the completion of the phase 3 trial in focal-onset seizures and the phase 2 trial in bipolar mania [39] Strategic Positioning - The company is positioned to execute its programs independently, with no immediate plans for partnerships, although it remains open to opportunities that do not compromise its initiatives [42][43][44]
Rapport Therapeutics (NasdaqGM:RAPP) FY Conference Transcript